| Total N = 373 | CRF01_AE n = 188 | Non-CRF01_AE n = 185 | P-value |
---|---|---|---|---|
Sex n(%) | Â | Â | Â | 0.429 |
 Male | 263 (70.5) | 129 (68.6) | 134 (72.4) |  |
 Female | 110 (29.5) | 59 (31.4) | 51 (27.6) |  |
 Age years | 35 (27–43) | 35 (28–43) | 36 (27–43) | 0.893 |
Ethnic category n(%) | Â | Â | Â | 0.655 |
 Han | 321 (86.1) | 157 (83.5) | 164 (88.6) |  |
 Minority | 52 (13.9) | 31 (16.5) | 21 (11.4) |  |
Route of Transmission n(%) | Â | Â | Â | 0.002 |
MSM | 120 (32.2) | 65 (34.6) | 55 (29.7) | Â |
Heterosexual | 195 (52.3) | 106 (56.4) | 89 (48.1) | Â |
Others | 58 (15.5) | 17 (9.0) | 41 (22.2) | Â |
Time between diagnosis and ART initiation (years) | 0.26 (0.99–1.18) | 0.32 (0.11–1.57) | 0.22 (0.09–0.97) | 0.245 |
Baseline HIV-1 DNA log10 copies/mL | 3.0 (2.6–3.4) | 3.19 (2.7–3.5) | 2.95 (2.6–3.2) | 0.000 |
Baseline plasma viral load log10 copies/mL | 4.6 (4.2–5.1) | 4.83 (4.4–5.2) | 4.49 (3.8–4.9) | 0.000 |
Baseline CD4+ T cell count cells/μL | 214 (129–299) | 193 (103–286) | 246 (157–206) | 0.001 |
Baseline CD8+ T-cell count cells/μL | 788 (530–1080) | 733 (526–1058) | 835 (545–1113) | 0.391 |
Baseline CD4/CD8 ratio | 0.24 (0.15–0.37) | 0.23 (0.11–0.35) | 0.27 (0.18–0.41) | 0.006 |
96-week HIV-1 DNA log10 copies/mL | 2.53 (2.09–2.91) | 2.63 (2.21–2.97) | 2.39 (2.00–2.80) | 0.002 |